23 November 2011
HealthLinx Limited (ASX:HTX) has signed legally binding Heads of Agreement with Oryzon Genomics for the distribution of OvPlex™ in Spain, with the option to extend exclusive license rights to Portugal, Andorra, France and Italy. HealthLinx expects to execute the legal distribution agreement by early in the new year, with distribution to begin in Spain in 2012.
Oryzon Genomics is a biopharmaceutical company based in Barcelona, Spain and is focused on the exploitation of biomarkers identified through genomics and proteomics in three fields: diagnostics, personalised medicine and therapy. Oryzon currently has four other diagnostic cancer biomarker tests (endometrial, colorectal, bladder and prostate) in various stages of pipeline development, with their endometrial cancer test due to be released in Q1 2012.
“Oryzon’s knowledge of the biomarker space and, more importantly, early stage cancer diagnostic tests appealed greatly as distribution partners” said HealthLinx managing director Nick Gatsios. “Such knowledge means that the product will be marketed clearly and effectively to the right clinicians and gynecological oncologists, which should mean the women in Spain who are most at risk are aware, and can use, OvPlex™ from day one of sales” Mr Gatsios added.
The market for ovarian cancer diagnostics in Spain is approximately 175,000 tests annually. In the jurisdictions combined, the opportunity increases to approximately 500,000 tests.